About atai beckley nv - ATAI
Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.
ATAI At a Glance
Atai Beckley, Inc.
250 West 34th Street
New York, New York 10119
| Phone | 1-929-207-2670 | Revenue | 4.09M | |
| Industry | Pharmaceuticals: Major | Net Income | -660,047,000.01 | |
| Sector | Health Technology | 2025 Sales Growth | 1,227.597% | |
| Fiscal Year-end | 12 / 2026 | Employees | 99 | |
| View SEC Filings |
ATAI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 226.588 |
| Price to Book Ratio | 6.697 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -5.95 |
| Enterprise Value to Sales | 164.509 |
| Total Debt to Enterprise Value | 0.003 |
ATAI Efficiency
| Revenue/Employee | 41,303.03 |
| Income Per Employee | -6,667,141.414 |
| Receivables Turnover | 0.283 |
| Total Asset Turnover | 0.017 |
ATAI Liquidity
| Current Ratio | 11.742 |
| Quick Ratio | 11.742 |
| Cash Ratio | 10.905 |
ATAI Profitability
| Gross Margin | 75.251 |
| Operating Margin | -2,789.46 |
| Pretax Margin | -16,137.173 |
| Net Margin | -16,142.015 |
| Return on Assets | -280.915 |
| Return on Equity | -390.363 |
| Return on Total Capital | -294.735 |
| Return on Invested Capital | -372.028 |
ATAI Capital Structure
| Total Debt to Total Equity | 0.934 |
| Total Debt to Total Capital | 0.925 |
| Total Debt to Total Assets | 0.667 |
| Long-Term Debt to Equity | 0.812 |
| Long-Term Debt to Total Capital | 0.804 |